The National Eczema Association details seven different kinds of eczema on its website, noting that atopic dermatitis is most common, affecting about half of eczema sufferers.
Organon & Co. ($OGN) announced an update on their ongoing clinical study. Organon & Co. has initiated a Phase 3 clinical study titled A ...
Sanofi ($SNYNF) announced an update on their ongoing clinical study. Sanofi’s recent clinical study, officially titled ‘A Phase 3, Randomized, ...
Emirates Drug Establishment Approves Tapinarof Cream 1%, A New Treatment For Plaque Psoriasis In Adults And Atopic Dermatitis ...
Organon’s latest valuation update nudges its fair value estimate down from $9.67 to $9.36 and edges the discount rate up from 10.20% to 10.25%, a small but telling shift that mirrors Wall Street’s ...
Ruxolitinib cream demonstrated favorable safety and efficacy in pediatric atopic dermatitis, highlighting JAK inhibitors' ...
Kymera Therapeutics receives US FDA Fast Track Designation for KT-621, an oral STAT6 degrader to treat atopic dermatitis: Watertown, Massachusetts Saturday, December 13, 2025, 18: ...
KYMR gains momentum as the FDA grants Fast Track to KT-621 for moderate to severe atopic dermatitis, boosting the stock and advancing its Type 2 pipeline.
Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD) (OTCQB: DVHGF), today announced operating and financial ...
In atopic dermatitis, the first interleukin-22 inhibitor to reach late clinical trials is showing uncommonly broad suppression of biomarkers associated with disease activity.
Alphyn Biologics, Inc., a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics (R) , today announced the close of its $25 million, twice-oversubscribed Series B ...
A research team led by Erwin F. Wagner from the Medical University of Vienna has discovered a previously unknown molecular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback